Ipamorelin and CJC-1295 Research Guide | Signal Labs
Ipamorelin and CJC-1295 act at complementary receptors in the GH axis — GHS-R1a and GHRHR respectively. This research guide examines their distinct mechanisms, receptor pharmacology, and how they are studied together.
Ipamorelin and CJC-1295 Research: GH Axis Dual-Receptor Pharmacology
Ipamorelin and CJC-1295 are the most frequently co-studied compounds in growth hormone axis research. Their popularity as a research pairing reflects a fundamental principle of GH axis pharmacology: GHS-R1a (the ghrelin receptor) and GHRHR (the GHRH receptor) represent two distinct but synergistic inputs to pituitary somatotroph GH release, and activating both simultaneously produces additive or superadditive GH output compared to either alone.
The Two GH Axis Receptors
GHS-R1a (Growth Hormone Secretagogue Receptor type 1a) is the target of Ipamorelin. It is a Gq/11-coupled GPCR that, upon activation, triggers phospholipase C, IP3-mediated calcium release, and PKC activation. Its endogenous ligand is ghrelin — a 28 amino acid peptide with an essential octanoyl modification at Ser3. GHS-R1a is expressed predominantly in the pituitary and hypothalamus, with additional expression in heart, stomach, and other tissues.
GHRHR (Growth Hormone Releasing Hormone Receptor) is the target of CJC-1295 variants. It is a Gs-coupled class B GPCR on pituitary somatotroph cells that, upon activation, raises intracellular cAMP and activates PKA, leading to GH gene transcription and secretory granule exocytosis. Its endogenous ligand is GHRH — a 44 amino acid hypothalamic peptide.
These two receptors activate GH release through different intracellular pathways (calcium/PKC via GHS-R1a versus cAMP/PKA via GHRHR), which is the mechanistic basis for their synergistic GH-releasing effects when both are activated simultaneously.
Ipamorelin: Receptor Selectivity Profile
What distinguishes Ipamorelin from earlier growth hormone releasing peptides (GHRPs) is its receptor selectivity. GHRP-2, GHRP-6, and Hexarelin all activate GHS-R1a but also stimulate ACTH release (leading to cortisol elevation), prolactin secretion, and aldosterone release to varying degrees. These off-target activities complicate their use as isolated GHS-R1a research tools.
| Compound | GHS-R1a | ACTH/cortisol | Prolactin | Aldosterone |
|---|---|---|---|---|
| Ipamorelin | High | Minimal | Minimal | Minimal |
| GHRP-2 | High | Moderate | Moderate | Low |
| GHRP-6 | High | Low | Moderate | Low |
| Hexarelin | High | High | High | Moderate |
Ipamorelin's selectivity makes it the preferred GHS-R1a agonist for research requiring isolated GH axis stimulation without confounding effects on the HPA axis or prolactin system.
CJC-1295 Variants: No DAC vs With DAC
Two variants of CJC-1295 are available, differing primarily in their plasma half-life and the GH secretion pattern they produce.
CJC-1295 (No DAC) — also known as Modified GRF 1-29 — has an approximately 30 minute plasma half-life and produces discrete pulsatile GH release following each administration. This mirrors the physiological pattern of GH secretion and is preferred for research examining pulse-dependent GH biology.
CJC-1295 (With DAC) incorporates a maleimidopropionic acid (MPA) linker that covalently bonds to Cys-34 of serum albumin, extending the half-life to approximately 8 days and producing sustained GH elevation. This variant is preferred for chronic dosing studies and research examining receptor desensitisation and long-duration IGF-1 responses.
| Property | CJC-1295 No DAC | CJC-1295 With DAC |
|---|---|---|
| Half-life | ~30 minutes | ~8 days |
| GH pattern | Pulsatile | Sustained |
| Albumin binding | No | Covalent (Cys-34) |
| Best for | Pulse biology research | Chronic/long-duration studies |
| MW | 3367.9 g/mol | 3647.1 g/mol |
Synergistic Dual-Receptor Research
The published rationale for combining Ipamorelin with CJC-1295 in research is that GHS-R1a and GHRHR have complementary and synergistic mechanisms. GHS-R1a activation additionally suppresses somatostatin release from the hypothalamus — removing the inhibitory tone that normally limits GHRHR-mediated GH release. This means Ipamorelin primes the system for enhanced response to CJC-1295 by reducing somatostatin inhibition simultaneously with GHS-R1a-mediated GH stimulation.
Counterintuitively, published research (Ionescu and Frohman, JCEM 2006) demonstrated that pulsatile GH secretion persists even during continuous GHRHR stimulation from CJC-1295 (With DAC). This finding — that GH pulsatility is maintained by hypothalamic somatostatin pacemaker activity regardless of sustained GHRHR occupancy — has been important in understanding the neural control of GH secretion.
Research Applications
Combined Ipamorelin and CJC-1295 research is used to study GH axis pharmacology and receptor synergism, pituitary somatotroph cell responses to dual receptor activation, the role of somatostatin suppression in GH axis pharmacodynamics, downstream IGF-1 axis responses to dual-receptor GH stimulation, and comparative pharmacodynamics of pulsatile (No DAC) versus sustained (With DAC) GH release.
Published Research References
GHS-R1a Structure and Ghrelin Biology
Understanding GHS-R1a biology is essential context for Ipamorelin research. GHS-R1a was first identified as an orphan receptor in 1996 by Howard et al. (Science, 1996) using synthetic GHRPs including GHRP-6 as tool compounds — the receptor was cloned before its natural ligand was identified. Ghrelin, the endogenous GHS-R1a ligand, was subsequently discovered in 1999 by Kojima et al. (Nature, 1999) — notable for being one of the few cases in biology where a receptor was discovered before its ligand.
Ghrelin is a 28 amino acid peptide with an unusual octanoyl modification at Ser3 — one of only a handful of known mammalian hormones with a fatty acid modification. This octanoylation is essential for GHS-R1a binding and is catalysed by ghrelin O-acyltransferase (GOAT). Unghrelin (des-acyl ghrelin, the non-octanoylated form) does not activate GHS-R1a and has distinct biological effects.
Research relevance: Ipamorelin mimics the GHS-R1a-activating properties of ghrelin's octanoylated form without the fatty acid modification, using its D-2-Naphthylalanine at position 3 to occupy the hydrophobic pocket in GHS-R1a that normally accommodates the octanoyl chain. This makes Ipamorelin a useful tool for isolating GHS-R1a pharmacology from the pleiotropic effects of native ghrelin.
CJC-1295 No DAC vs Sermorelin: Modification Contributions
The four modifications in CJC-1295 No DAC versus native Sermorelin each address a specific stability vulnerability. Research using both compounds allows systematic characterisation of modification contributions:
D-Ala2 (blocks DPP-IV cleavage): The primary stability improvement. Running parallel experiments with Sermorelin (DPP-IV-sensitive), Sermorelin + sitagliptin (DPP-IV inhibited), and CJC-1295 No DAC allows quantification of the DPP-IV contribution to GHRH half-life and pharmacodynamics.
Gln8 (prevents deamidation at Asn8): Relevant for long-term storage stability. Deamidated Sermorelin (Asn8→Asp8) has altered charge and slightly different GHRHR binding. Research comparing freshly prepared versus stored Sermorelin can detect deamidation-related activity loss.
Ala15 (backbone stability): Reduces conformational flexibility, potentially improving receptor binding geometry. Less amenable to direct study than the DPP-IV site modification.
Leu27 (prevents Met27 oxidation): Particularly relevant for oxidative stability studies. Met-containing peptides (Sermorelin has Met27) are susceptible to oxidation under storage or assay conditions with dissolved oxygen. Comparing Sermorelin and CJC-1295 No DAC under oxidative conditions quantifies this contribution.
Somatostatin Pacemaker: Why GH Remains Pulsatile
The landmark finding by Ionescu and Frohman (JCEM, 2006) — that GH secretion remains pulsatile even during sustained GHRHR stimulation from CJC-1295 — has profound implications for understanding the CJC-1295 + Ipamorelin combination. This finding established that GH pulsatility is driven by the hypothalamic somatostatin oscillator, not by GHRHR receptor availability.
Somatostatin neurons in the periventricular nucleus of the hypothalamus fire in a rhythmic pattern (approximately every 3-4 hours in humans), releasing somatostatin into the portal circulation that transiently suppresses pituitary GH release. Between somatostatin pulses, when somatostatin tone is low, GH is released from the pituitary — driven by GHRH and, in the combination paradigm, enhanced by Ipamorelin-mediated somatostatin suppression.
The GH pulse profile from CJC-1295 No DAC + Ipamorelin thus reflects: (1) amplified GH release during low-somatostatin windows (Ipamorelin's GHS-R1a activation + somatostatin suppression), (2) maintained pulsatility dictated by hypothalamic somatostatin rhythm, and (3) sustained GHRHR occupancy from CJC-1295 No DAC ensuring the pituitary remains primed for GH release at each low-somatostatin window.
Published Research References
Key Published Research
Key Published Research
For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.
View Ipamorelin | View CJC-1295 (No DAC) | View CJC-1295 (With DAC)